| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5655661 | Digestive and Liver Disease | 2017 | 21 Pages |
Abstract
This study suggests that gemcitabine is not beneficial to all patients failing on Folfirinox first-line therapy and should be restricted to young patients with good PS.
Related Topics
Health Sciences
Medicine and Dentistry
Endocrinology, Diabetes and Metabolism
Authors
Juliette Viaud, Clémence Brac, Pascal Artru, Estelle Le Pabic, Bérengère Leconte, Anaïs Bodère, Marc Pracht, Samuel Le Sourd, Julien Edeline, Astrid Lièvre,